Ferenci P, Grimm G
Universitätsklinik für Gastroenterologie und Hepatologie, Universität Wien.
Leber Magen Darm. 1989 Dec;19(6):322-5.
For the first time a causal treatment of hepatic encephalopathy may be possible by the benzodiazepine antagonist flumazenil. In contrast to all other treatments used so far by flumazenil hepatic encephalopathy improves within minutes. Flumazenil is the first benzodiazepine antagonist which can be used in humans and is a well established for treatment of benzodiazepine overdose. For treatment of hepatic encephalopathy development of a new antagonist with a longer half-life is desirable. However, ut should be stressed that the current experience with flumazenil is limited and that the effects of flumazenil on hepatic encephalopathy is not proven by randomized controlled studies. Therefore, this drug should only be used in clinical studies.
苯二氮䓬拮抗剂氟马西尼首次使对肝性脑病进行病因治疗成为可能。与迄今为止使用的所有其他治疗方法不同,使用氟马西尼后肝性脑病在数分钟内即可改善。氟马西尼是首个可用于人类的苯二氮䓬拮抗剂,且已被广泛用于治疗苯二氮䓬过量。为治疗肝性脑病,研发半衰期更长的新型拮抗剂是很有必要的。然而,应当强调的是,目前关于氟马西尼的经验有限,且氟马西尼对肝性脑病的作用尚未得到随机对照研究的证实。因此,这种药物仅应用于临床研究。